Press Room

Tracking CMT4J from the Inside Out: What MRI Scans Are Showing So Far With CMTA support of $149,443, researchers at CMTA Strategy To Accelerate Research (CMTA-STAR) Alliance Partner Elpida Therapeutics are investigating muscle fat fraction (MFF) ...

The Charcot-Marie-Tooth Association (CMTA), the world’s largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research, is proud to share that Kailee Ward, Genetic Counseling Assistant at CMTA’s Center of Excellence at the University of Iowa Hospitals ...

CMT news out of Belgium: Augustine Therapeutics has officially dosed the first participant in a Phase I clinical trial of AGT-100216, the company’s experimental drug in development for Charcot-Marie-Tooth disease (CMT). According to the company, AGT-100216 ...

The Charcot-Marie-Tooth Association (CMTA) congratulates CMTA Strategy To Accelerate Research (CMTA-STAR) Alliance Partner Applied Therapeutics on presenting new 24-month results from its Phase III CMT-SORD clinical trial at the 2025 Annual Meeting of the Peripheral ...

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth (CMT) disease research, presented a new analysis of the genetic landscape of CMT at the 2025 Annual Meeting of the Peripheral Nerve Society (PNS). The poster ...